---
title: Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment
nct_id: NCT01962181
overall_status: UNKNOWN
phase: NA
sponsor: Hadassah Medical Organization
study_type: INTERVENTIONAL
primary_condition: "\"Attention Deficit Hyperactivity Disorder\""
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01962181.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01962181"
ct_last_update_post_date: 2013-10-14
last_seen_at: "2026-05-12T06:30:06.918Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

**Official Title:** Identifying Characteristic Signature of Brain Activity of Electroencephalogram Records in Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

**NCT ID:** [NCT01962181](https://clinicaltrials.gov/study/NCT01962181)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Hadassah Medical Organization
- **Conditions:** "Attention Deficit Hyperactivity Disorder"
- **Start Date:** 2013-10
- **Completion Date:** 2015-12
- **CT.gov Last Update:** 2013-10-14

## Brief Summary

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment.

## Detailed Description

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment. All subjects will undergo 1-4 EEG sessions. In each session we will use a different dose of Ritalin or placebo. A detailed neuropsychological tests will be done during the EEG recording. A powerful machine-learning techniques will be used in order to find a specific signature of ADHD and Ritalin treatment in the EEG recording.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy subjects, aged 18-50 years.
* Subjects aged 18-50 years diagnosed with ADHD and treated with Ritalin regularly (at least once a week).

Exclusion Criteria:

* Patients previously diagnosed as suffering from a brain disease except for ADHD.
* Patients after traumatic head injury.
* Patients who are unable to express their consent to participate in the study.
```

## Arms

- **Ritalin** (ACTIVE_COMPARATOR) — Ritalin treatment at different doses
- **Placebo** (PLACEBO_COMPARATOR) — Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.

## Interventions

- **Ritalin** (DRUG) — Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
- **Placebo** (DRUG)

## Primary Outcomes

- **Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects.** _(time frame: 2 years)_ — The primary outcome measure is the difference in the analysis of EEG recording (for example, resting oscillation activity and Event-related-Potentials) in Attention Deficit / Hyperactivity Disorder (ADHD) vs. healthy subjects.

## Locations (1)

- Hadassah Medical Center, Jerusalem, Israel, Israel

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.hadassah medical center|jerusalem|israel|israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01962181.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01962181*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*